Taylor Jensen
Vice President, Head of Science Enterprise Oncology Labcorp
Seminars
Wednesday 4th February 2026
Leveraging Ultrasensitive Liquid Biopsy Solutions for Longitudinal Monitoring & Treatment Response in Global Testing
3:45 pm
- Learn about clinically validated liquid biopsy CGP and MRD solutions developed to support global patient management clinical trials
- Explore the latest data demonstrating how parallel sequencing of plasma and buffy coat can filter CH variants for more accurate variant detection to enable monitoring and treatment response
- Review early updates on improved sensitivity of MRD applications for earlier detection of relapse, novel endpoints and precise treatment decision
